Jul 14, 2022 / 11:00AM GMT
Jonas Jarvius - Q-linea AB - CEO
Welcome everyone to our Q2 earnings call. I think we'll start jumping directly into the presentation, and we move to slide number two, where you can also, of course, read our disclaimer slide -- and that is in case me or Anders we make any forward-looking statements.
Having read through that, I suggest we move to slide number three, where we have a high-level summary over the second quarter. And it's truly been an amazing quarter for Q-linea. As you know, we are working hard to develop disruptive solutions for faster infectious disease diagnostics. Our first product is targeting sepsis, and I will briefly give an overview of ASTar over the next coming slides.
The team working at Q-linea, having175 employees and consultants are slightly lower compared to the last quarter. And I will also comment on that at the end of the call. But looking into the activities during the second quarter, we have been exhibiting ASTar. Of course, our partner, Thermo Fisher Scientific has done that as well -- both ECCMID and ASM and they have been very successful. We also
Q2 2022 Q linea AB Earnings Call Transcript
Mar 01, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers